Effect of cannabis oil on untreatable liver cancer
Official title: A Phase 2a Study on the Anti-tumoral Effect of Cannabis Oil (THC 10% / CBD 5%) in Patients With Advanced Untreatable Hepatocellular Carcinoma
Run by University Medical Center Groningen · NCT06518434 · Data updated 2026-11-12
This study tests whether cannabis oil can help people with untreatable liver cancer feel better by seeing if it affects their tumors.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University Medical Center Groningen Academic / other |
| Locations | 1 site (Groningen) |
| Status | Recruiting |
| Started | April 15, 2021 |
| Main results expected | April 15, 2027 |
| Study ends | April 15, 2027 |
| Registry record updated | July 24, 2024 |
| Trial ID | NCT06518434 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with histologically confirmed hepatocellular carcinoma who are unable to undergo standard treatments.
✕Probably not a fit
Patients with advanced cirrhosis (Child Pugh B or C) or significant hepatic encephalopathy are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study investigates the anti-tumor effects of cannabis oil containing THC and CBD in patients with untreatable hepatocellular carcinoma (HCC). The study will assess the efficacy of the treatment using mRECIST and RECIST criteria to evaluate tumor response. Participants will receive best supportive care while being monitored for any changes in their condition. The study aims to provide insights into the potential role of cannabis oil in managing advanced liver cancer.
Why it matters
Potential benefit: If successful, this study could offer a new therapeutic option for patients with advanced liver cancer who have limited treatment choices.
How similar studies have gone: While the use of cannabis oil in cancer treatment is being explored, this specific approach in untreatable liver cancer is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age =\>18 yrs * Histologically proven hepatocellular carcinoma * Non-cirrhosis or Child Pugh A cirrhosis * Hepatic encephalopathy grade 0 or 1 * Multidisciplinary treatment (MDT)-advised best supportive care for untreatable advanced HCC or patients unable to undergo or declining treatment for advanced HCC. * Minimal life expectancy of 3 months * Willing and able to attend follow-up examinations * Willing to stop active traffic participation or controlling machinery during the study period if applicable * Signed informed consent * Language: Dutch or English Exclusion Criteria: * Child Pugh B or C cirrhosis * Hepatic encephalopathy grade 2 or more * Previous systemic treatment for HCC * Mental conditions rendering the subject incapable to understand the nature, scope and consequences of the trial * Use of medicinal cannabis for other purposes * Contra-indications for medicinal cannabis oil: * Patients who have experienced a myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or have had a cardiac disorder that, in the opinion of the investigator would have put the participant at risk of a clinically significant arrhythmia or myocardial infarction. * Patients with known psychotic disorders * Female patients who are pregnant or lactating * Patients (men or women) intending to start a family * Hypersensitivity to cannabinoids or any of the excipients of the cannabis oil
Where it's running
-
University Medical Center Groningen
Groningen, Netherlands Recruiting
Study contacts
- Principal investigator: M W Nijkamp, MD PhD — University Medical Center Groningen
- Study coordinator: M W Nijkamp, MD PhD
- Email: m.w.nijkamp@umcg.nl
- Phone: +31625649985
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Cannabis Effects on Recognition Memory and Brain Waves in Regular Users
This study tests how THC- and CBD-containing cannabis strains affect recognition memory and brain activity in regular cannabis users.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.